4770-32-5Relevant academic research and scientific papers
BROMODOMAIN INHIBITOR
-
Paragraph 0246, (2016/10/31)
The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.
Identification of a potent and selective 5-HT1B receptor antagonist
Wyman, Paul A.,Marshall, Howard R.,Flynn, Sean T.,King, Ron J.,Thompson, Mervyn,Smith, Paul W.,Hadley, Michael S.,Price, Gary W.,Scott, Claire M.,Dawson, Lee A.
, p. 4708 - 4712 (2007/10/03)
An SAR study around the mixed 5-HT1ABD receptor antagonist SB-272183 found that introduction of cis-2,6-dimethyl substitution onto the piperazine ring was a key structural change, which imparted a combination of both excellent selectivity over
